Please ensure Javascript is enabled for purposes of website accessibility

drug development

FILE PHOTO: Futures-options traders work on the floor at the New York Stock Exchange's NYSE American (AMEX) in New York City, U.S., January 13, 2026. REUTERS/Brendan McDermid/File Photo
Jan 14, 2026

US biotech sector poised for 2026 rebound as IPO interest revives

Investors see a potential biotech rebound in 2026 as IPO activity, dealmaking and lower rates offset lingering policy risks.

Novo ups bid to $10B in Metsera fight with Pfizer
Nov 4, 2025

Novo ups bid to $10B in Metsera fight with Pfizer

Novo Nordisk raised its offer to $10 billion for Metsera, escalating its takeover battle with Pfizer over the drug developer.

YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.